Pulmatrix, Inc. (PULM)

Market Cap	11.03M
Revenue (ttm)	4.82M
Net Income (ttm)	-21.85M
Shares Out	3.64M
EPS (ttm)	-6.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,185
Open	3.03
Previous Close	3.02
Day's Range	2.98 - 3.06
52-Week Range	2.97 - 7.50
Beta	0.89
Analysts	Buy
Price Target	10.20 (+236.63%)
Earnings Date	Apr 4, 2023

About PULM

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: PULM

Financial Performance

In 2021, Pulmatrix's revenue was $5.17 million, a decrease of -59.09% compared to the previous year's $12.63 million. Losses were -$23.37 million, 21.0% more than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for PULM stock is "Buy." The 12-month stock price forecast is $10.2, which is an increase of 236.63% from the latest price.

Price Target

$10.2

(236.63% upside)

Analyst Consensus: Buy